WO1989003678A1 - Low residual solvent microspheres and microencapsulation process - Google Patents
Low residual solvent microspheres and microencapsulation process Download PDFInfo
- Publication number
- WO1989003678A1 WO1989003678A1 PCT/US1988/003859 US8803859W WO8903678A1 WO 1989003678 A1 WO1989003678 A1 WO 1989003678A1 US 8803859 W US8803859 W US 8803859W WO 8903678 A1 WO8903678 A1 WO 8903678A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- solvent
- core material
- oil
- εaid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/20—After-treatment of capsule walls, e.g. hardening
- B01J13/206—Hardening; drying
Definitions
- the present invention relates to a method of icroencapsulating a core material to form a microsphere with reduced residual solvent and water content.
- Microencapsulation is the process of coating a core material with a thin layer of a separate, encapsulating material to form microcapsules.
- the microencapsulation process has many applications, particularly in the pharmaceutical industry.
- drugs are coated to obtain controlled-release of the drug, to improve chemical stability, and to permit the mixing and storage of reactive or incompatible drugs.
- phase separation process For water-soluble or miscible core material, the phase separation process generally involves the technique of dispersing the solid core material of the desired particle size or an aqueous solution or suspension in a polymeric coating material dissolved in an organic solvent. The polymeric material is then deposited on the core material by gradual precipitation of the polymer.. This is achieved by either the use of precipitants, by changes in tempera ⁇ ture, or by removal of the solvent by dilution or distillation. An example of this process is described in United States Patent No. 4,166,800 to Fong. In this patent, the polymer is precipitated by a phase separa ⁇ tion agent, a non-solvent for the polymer.
- U.S. Patent No. 4,518,547 to Cuff et al.. describes a process for the microencapsulation of a hydrophilic core material by interfacial polycondensation.
- the process comprises dissolving the core material in a hydrophilic solvent, water, preferably together with an inert carrier material and adding a water immiscible organic solvent to form droplets containing the core material.
- Two complementary polycondensation monomer reactants are then added either sequentially or simulta ⁇ neously which causes interfacial polymerization of a membrane encapsulating the core material.
- U.S. Patent No. 4,384,975 to Fong describes an oil- in-water emulsion process for producing icrospheres. This process comprises dissolving a polymer in a volatile, water-immiscible organic solvent in which the core material is not soluble; adding the core material; mixing the organic dispersion with an aqueous solution containing a carboxylic acid salt as the emulsifier to form a stable oil-in-water emulsion; and removing the organic solvent by evaporation to form the micro ⁇ capsules.
- U.S. Patent No. 4,389,330 to Tice et al.. describes a process for preparing microcapsules containing a water insoluble core material.
- a polymer is dissolved in an organic solvent.
- the core material is dispersed or dissolved in the polymer-organic solvent.
- This loaded mixture is then dispersed in a continuous- phase processing medium to form the microcapsules.
- the medium can be water or a non-aqueous media such as xylene or toluene or oils.
- the solvent is removed in a two-step removal process.
- European Patent Application No. 81/305426.9 describes a microencapsulation process of water soluble polypeptides.
- a polymer, the wall- forming material is dissolved in an organic solvent, methylene chloride.
- the core material is then added to the polymer-solvent solution.
- a non-solvent such as an oil compound which is soluble in the organic solvent, but is a non-solvent for the polymer is then added.
- the ratio of non-solvent to organic solvent is about 1:3.
- the microcapsules that are formed are then quenched by mixing them with heptane.
- This invention comprises a process for microencap- sulating a core material such that the resulting microcapsule has reduced residual solvent and reduced water content.
- the microsphere has reduced residual solvent with no residual water present. The process of this invention involves the steps of:
- the invention also comprises microspheres compris ⁇ ing a core material encapsulated by a polymer coating, the microspheres having a residual solvent content of, about one percent.
- the inventors have discovered that the use of synthetic oils or vegetable oil compounds as the first non-solvent in combination with the high ratio of the first non-solvent to the organic solvent for the polymeric coating material reduces the residual solvent in the final microsphere product. By use of this invention it is possible to reduce the level of residual solvent in the microspheres.
- the final microspheres when solid particles to be encapsulated are used, the final microspheres will have a reduced residual solvent with no residual water content.
- the invention also comprises microspheres comprising a core material encapsulated by a polymer coating, the microspheres having a reduced residual solvent content of about one percent and with no residual water present.
- the process of this invention is based on a phase separation technique to microencapsulate a core materi ⁇ al.
- the general process of this invention involves the following steps:
- the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product.
- a final microsphere product is produced that has a residual solvent level of less than one percent.
- residual solvent is meant the level of residual second non- solvent that remains in the final microsphere product.
- organic solvent typi ⁇ cally ethylene chloride.
- the methylene chloride level is vacuum extractable to 0.1 % or less.
- the ratios are based on a weight/weight ratio.
- the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product.
- a final microsphere product is produced that has a residual solvent level of less than one percent and a reduced water content.
- the core material that may be used in this inven ⁇ tion can include any material that is not soluble or miscible with the polymeric coating material or the organic solvent for the polymer or the first or second non-solvent for the polymer.
- the polymeric coating material that may be used in this invention may be either natural or synthetic polymers, or combinations thereof.
- the polymers may include cellulosic polymers, polyvinyl acetate, poly ⁇ vinyl alcohol, polyvinyl chloride, natural and synthetic rubbers, polyacrylates, polyorthoesters, and the like.
- polystyrene ethyl- cellulose, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylaminohydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly- (meth)acrylic acid ester, polyvinylacetal-diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate- etha ⁇ rylic acid copolymer, polycarbonate, polyesters, polypropylene, vinylchloride-vinylacetate copolymer, polysaccharides, and glycerol distearate.
- Suitable polymers for use with a pharmaceutical core material include biodegradable polymers such as polyanhydrides and aliphatic polyesters including polylactide, polylactide-co-glycolide polyglycolide, polycaprolactone, polylactide-co-caprolactone, poly- hydroxybutyride, polyanhydride, polydioxanone, and copolymers thereof such as poly(lactide-co-glycolide) copolymer and polylactide homopolymer.
- biodegradable polymers such as polyanhydrides and aliphatic polyesters including polylactide, polylactide-co-glycolide polyglycolide, polycaprolactone, polylactide-co-caprolactone, poly- hydroxybutyride, polyanhydride, polydioxanone, and copolymers thereof such as poly(lactide-co-glycolide) copolymer and polylactide homopolymer.
- the organic solvent that may be used according to this invention to dissolve the polymeric coating material must be a material which will dissolve the polymeric coating material and which will not dissolve the core material to be encapsulated. If the core material is a pharmaceutical compound, then the organic solvent must also be chemically inert with respect to any pharmaceutical compounds to be encapsulated.
- the organic solvent can be selected from a variety of common organic solvents including halogenated aliphatic hydrocarbons, typically the C ⁇ to c 4 halo ⁇ genated alkanes, such as, for example, chloroform, methylene chloride, ethylene dichloride, ethylene chloride, ethyl acetate, methylchloroform and the like; aromatic hydrocarbon compounds, halogenated aromatic hydrocarbon compounds; cyclic ethers such as tetrahydro- furan and the like.
- halogenated aliphatic hydrocarbons typically the C ⁇ to c 4 halo ⁇ genated alkanes, such as, for example, chloroform, methylene chloride, ethylene dichloride, ethylene chloride, ethyl acetate, methylchloroform and the like
- aromatic hydrocarbon compounds halogenated aromatic hydrocarbon compounds
- cyclic ethers such as tetrahydro- furan and the like.
- the first non-solvent for the polymer according to this invention may be selected from synthetic oils or vegetable oil compounds.
- Synthetic oils may include silicone oil, mineral oil, and petroleum oils.
- Vege ⁇ table oils may include sesame oil, peanut oil, soybean oil, corn oil, cotton seed oil, coconut oil, linseed oil, and other related oils.
- non-solvent is meant a solvent that is miscible with the organic solvent but is not a solvent for the polymeric coating or core materi ⁇ al.
- the inventors have discovered that the amount and type of the first non-solvent for the polymer controls the level of residual solvent (second non-solvent) in the final microsphere product.
- the ratio of first non-solvent to organic solvent is from about 1:5 to about 3:1. Further, in one embodiment of this invention, by employing solid drug particles rather than aqueous solutions or suspensions of drug, no residual water is present in the final product.
- the polymeric coating material is dissolved in the selected organic solvent prior to adding the core material.
- the amount of polymeric coating material dissolved in the solvent is typically from about 5 to 50 percent.
- the core material is then added to the polymer- solvent solution, preferably, as solid particles to form a suspension or as an aqueous solution to form a water- in-oil emulsion.
- the amount of core material added to the polymer-solvent solution is not critical, although the ratio of core material to polymer is important insofar as that at too high an amount of core material to polymer, microspheres will not form.
- the upper limit of the ratio of core material to polymer may be about 80 parts by weight core material to about 20 parts by weight polymer.
- core material is added to the polymer-solvent solution such that the core material comprises about 5 to 50 weight percent.
- the first non-solvent synthetic oil or vegetable oil, in an amount of the ratio of about 1:5 to about 3:0, first non-solvent to organic solvent, is then added slowly to the mixture of polymeric solvent solution with the added core material.
- the first non-solvent causes the polymeric material to precipitate out of the organic solvent onto the core material, thereby encapsulating the core material.
- the first non-solvent is added under carefully controlled conditions of temperature, rate, and stir speed. For example, temperature conditions may range from -20 degrees C to +30 degrees C; rate 5 g/minutes per g of batch; stir speed from 400 to 2500 rpm.
- the microspheres are treated in a quenching step to harden them.
- the microspheres are quenched with a second non-solvent. This second non-solvent hardens the microspheres and extracts the solvent from the microspheres and yet does not dissolve the microspheres (wall material or core material) .
- the amount of second non-solvent added in this quenching step is typically from about 0.251/g of batch to about 1 1/g of batch.
- Suitable second non-solvents include heptane and aliphatic hydrocarbons such as hexanes.
- the microspheres are isolated, such as by filtration or sieving, and are dried by exposure to air or by other conventional drying techniques, such as vacuum drying, drying over a dessicant, or the like.
- the microspheres are dried under a vacuum at room temperature to further reduce the level of organic solvent in the final microsphere product.
- the process of this invention a final microsphere product is produced that contains about one percent residual solvent.
- the inal microsphere product contains about one percent residual solvent with no residual water present.
- the microsphere product of the present invention is usually made up of particles of a spherical shape although sometimes the microspheres may be irregularly shaped.
- the microspheres can vary in size, ranging from sub- micron to millimeter diameters. Preferably, ⁇ ubmicron to 250 urn diameters are desirable for pharmaceutical formulations allowing administration of the microspheres with a standard syringe and needle.
- the microspheres find utility in a wide variety of applications depending upon the encapsulated core compound.
- the microsphere product, according to this invention is an encapsulated pharmaceutical compound which can be administered to both humans and animals.
- the core material that may be used in the process of this invention may include agricultural agents, such as insecticides, fungicides, herbicides, rodenticides, pesticides, fertilizers, and viruses for crop protection and the like; cosmetic agents, such as deodorants, fragrances, and the like; food additives such as flavors; and pharmaceutical agents.
- Pharmaceutical compounds are the preferred core materials of the process according to this invention. These compounds may also include the non-toxic pharma ⁇ ceutically acceptable acid addition salts, such as hydrochloride, ⁇ ulfate, phosphate, succinate, benzoate, acetate, pamoate, fu erate, mesylate, and the like.
- non-toxic pharma ⁇ ceutically acceptable acid addition salts such as hydrochloride, ⁇ ulfate, phosphate, succinate, benzoate, acetate, pamoate, fu erate, mesylate, and the like.
- contraceptive agents including estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol, and the like; progestins such as norethindrone, norgestryl, ethynodiol diacetate, lynestrenol, medroxyprogesterone acetate, dimethi- sterone, megestrol acetate, chlormadinone acetate, norgestimate, norethisterone, ethisterone, melengestrol, norethynodrel and the like; and spermicidal compounds such as nonylphenoxypolyoxyethylene glycol, benzethoniu chloride, chlorindanol and the like.
- estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol,
- gastrointestinal therapeutic agents such as aluminum hydroxide, calcium carbonate, magnesium carbonate, sodium carbonate and the like; non- steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; major tranquilizers such as chloropromazine HC1, clozapine, mesoridazine, metiapine, reserpine, thioridazine and the like; micro tranquilizers such as chlordiazepoxide, diazepam, meprobamate, temezepam and the like; rhinological decongestants, sedative-hypnotics such as codeine, phenobarbital, sodium pentobarbital, sodium secobarbital and the like; other steroids such as testosterone and testosterone propionate; sulfonamides; sympathomimetic agents; vaccines; vitamins and nutrients such as the essential amino acids, essential fats and the like; antimalarials such as
- narcotics such as codeine, dihydrocodienone, meperidine, morphine and the like
- non-narcotics such as ⁇ ali ⁇ ylates, aspirin, acetamino ⁇ phen, d-propoxyphene and the like
- antibiotics such as the cephalosporins, chloranphenical, gentamicin, Kanamycin A, Kanamycin B, the penicillins, ampicillin, streptomycin A, antimycin A, chloropamtheniol, metromi- dazole, oxytetracycline penicillin G, the tetracyclines, and the like
- anti-cancer agent anti-convulsants such as mephenytoin, phenobarbital, trimethadione
- anti- emetics such as thietylperazine
- antihistamines such as chlorophinazine, dimenhydrinate
- Mvcobacterium tuberculosis Herpes virus (hu onis, types 1 and 2), Candida albicans. Candida tropicalis. Trichomonas vaqinalis. Haemophilus vaginalis. Group B streptococcus E. coli. gtrep. mutans. Microplasma hominis. He ⁇ ophilus ducreyi. Granuloma inguinale, Lv phopathia venereum, Treponema pallidum. Brucella abortus,. Brucella ⁇ ieliten- sis. Brucella suis. Brucella canis. Ca pylobacter fetus. Campylobacter fetus intestinalis.
- Leptospira pomona Listeria moncvtoqenes. Brucella ovis. Equine herpes virus 1, Equine arteritis virus, IBR-IBP virus, BVD-MB virus, Chlamvdia psittaci. Trichomonas foetus. Toxo- plasma ⁇ ondii. Escherichia coli. Actinobaccillus e uuli. Salmonella abortus ovis. Salmonella abortus e ⁇ ui. Pseudomonas aeruginosa. Corynebacterium equi. Corvnebac- terium pyogenes. Actinobaccilus seminis.
- hormon- ally active polypeptides especially luteininzing hormone-releasing hormone (LR-RH) polypeptides, ana ⁇ logues, and antagonists thereof; mammalian growth hormones, including human, bovine, equine, and sheep growth hormones; alpha, beta, gamma, and omega interferon; interleukin I and interleukin II; and erythropoietin.
- LR-RH luteininzing hormone-releasing hormone
- This example describes the procedure for preparing microspheres, varying the ratio of the first non- solvent, silicone oil, to the organic ⁇ olvent, methylene chloride.
- the polymeric coating material a copolymer with a 50:50 molar ratio of lactide:glycolide units with inherent viscosity of 0.69 dl/g, was weighed and dissolved in methylene chloride (CH 2 Cl 2 ) .
- the ratio of the silicone oil to the methylene chloride ⁇ olvent was varied in these experiments and the result ⁇ are shown in the following Table 1.
- the ⁇ ilicone oil cau ⁇ ed the polymer to pha ⁇ e separate, and depo ⁇ it as droplets of solvent-fluid polymer onto the surface of the water- ⁇ oluble microdroplet ⁇ . These solvent-fluid polymer droplets then coalesced to form a continuous film around the water-soluble microdroplets.
- microspheres were then hardened by quenching by pouring the contents of this first mixture into a beaker containing heptane.
- the heptane/methylene chloride/- ⁇ ilicone oil ⁇ olution wa ⁇ removed by filtration.
- the microspheres were further washed with aliquots of heptane.
- the microspheres were dried at room tempera ⁇ ture under vacuum.
- the microsphere ⁇ obtained from this preparation were determined to have diameters ranging in size from 25 to 150 microns.
- Table 1 gives the result ⁇ of the te ⁇ ting ⁇ to ⁇ how the effect of the ratio of eilicone oil to methylene chloride and the effect of the vi ⁇ cosity of the ⁇ ilicone oil.
- the vi ⁇ co ⁇ ity of the ⁇ ilicone oil was studied at 200c ⁇ , 350cs, and 500cs. In three of the tests, histrelin was used as the encapsulate; with the other test ⁇ a placebo was used.
- a 50:50 lactide:glycolide copolymer, 1.80 g, was dis ⁇ olved in 15.7 g of methylene chloride and charged to a 100 ml flask. Histrelin, 200.4 mg, was suspended in 12.2 g of methylene chloride and added with ⁇ tirring to the polymer ⁇ olution. An additional 6.0 g of methylene chloride wa ⁇ then added (total 33.9 g) . Silicone oil (350 cs), 13.13 g was added over 8.5 minutes. Then, the contents of the reaction flask were tran ⁇ ferred to 2800 ml of n-heptane with ⁇ tirring at 21*C. Stirring was continued for 3 hours.
- micro ⁇ pheres were collected on stain ess- ⁇ teel sieves and allowed to air dry.
- the re ⁇ idual heptane content wa ⁇ found to be 8.7% by weight.
- the hi ⁇ trelin content was 7.76% by weight.
Abstract
This invention is the process for the preparation of microcapsules with a reduced residual solvent level, having a core compound encapsulated by a polymer coating which comprises, dissolving the polymer in an organic solvent in which the core compound is not soluble; adding the core compound; adding a first non-solvent of the polymer and core material selected from synthetic oil or vegetable oil in a ratio of first non-solvent to organic solvent of from about 1.5:1 wt/wt to about 2.5:1 wt/wt to form microcapsules; and adding a second non-solvent of the polymer. The invention is also directed to microcapsules comprising a core compound encapsulated by a polymer coating, with the microcapsule having a residual solvent content of less than one percent. The invention is particularly useful for encapsulating pharmaceutical materials in biodegradable polymers.
Description
LOW RESIDUAL SOLVENT MICROSPHERES AND MICROENCAPSULATION PROCESS
FIELD OF INVENTION
The present invention relates to a method of icroencapsulating a core material to form a microsphere with reduced residual solvent and water content.
BACKGROUND OF THE INVENTION
Microencapsulation is the process of coating a core material with a thin layer of a separate, encapsulating material to form microcapsules. The microencapsulation process has many applications, particularly in the pharmaceutical industry. In a pharmaceutical applica¬ tion, drugs are coated to obtain controlled-release of the drug, to improve chemical stability, and to permit the mixing and storage of reactive or incompatible drugs.
One of the methods of microencapsulation is a phase separation technique. For water-soluble or miscible core material, the phase separation process generally involves the technique of dispersing the solid core material of the desired particle size or an aqueous solution or suspension in a polymeric coating material dissolved in an organic solvent. The polymeric material is then deposited on the core material by gradual
precipitation of the polymer.. This is achieved by either the use of precipitants, by changes in tempera¬ ture, or by removal of the solvent by dilution or distillation. An example of this process is described in United States Patent No. 4,166,800 to Fong. In this patent, the polymer is precipitated by a phase separa¬ tion agent, a non-solvent for the polymer.
U.S. Patent No. 4,518,547 to Cuff et al.. describes a process for the microencapsulation of a hydrophilic core material by interfacial polycondensation. The process comprises dissolving the core material in a hydrophilic solvent, water, preferably together with an inert carrier material and adding a water immiscible organic solvent to form droplets containing the core material. Two complementary polycondensation monomer reactants are then added either sequentially or simulta¬ neously which causes interfacial polymerization of a membrane encapsulating the core material.
U.S. Patent No. 4,384,975 to Fong describes an oil- in-water emulsion process for producing icrospheres. This process comprises dissolving a polymer in a volatile, water-immiscible organic solvent in which the core material is not soluble; adding the core material; mixing the organic dispersion with an aqueous solution containing a carboxylic acid salt as the emulsifier to form a stable oil-in-water emulsion; and removing the organic solvent by evaporation to form the micro¬ capsules.
U.S. Patent No. 4,389,330 to Tice et al.. describes a process for preparing microcapsules containing a water insoluble core material. In this process, a polymer is dissolved in an organic solvent. The core material is dispersed or dissolved in the polymer-organic solvent.
This loaded mixture is then dispersed in a continuous- phase processing medium to form the microcapsules. The medium can be water or a non-aqueous media such as xylene or toluene or oils. The solvent is removed in a two-step removal process.
European Patent Application No. 81/305426.9 describes a microencapsulation process of water soluble polypeptides. In this procedure, a polymer, the wall- forming material, is dissolved in an organic solvent, methylene chloride. The core material is then added to the polymer-solvent solution. A non-solvent such as an oil compound which is soluble in the organic solvent, but is a non-solvent for the polymer is then added. In Example I, the ratio of non-solvent to organic solvent is about 1:3. The microcapsules that are formed are then quenched by mixing them with heptane.
With conventional phase separation encapsulation techniques, especially when used to microencapsulate a pharmaceutical water-soluble drug, there is a high solvent residue. A need, therefore, has continued to exist for a technique of preparing microcapsules and microspheres of high quality, with reduced residual solvent. Further, with microcapsules and microspheres encapsulated with biodegradable polymers, it is desir¬ able to avoid water in the finished product in order to enhance product stability. Water present in the biodegradable polymers will typically cause the polymers to hydrolize; for example, the mechanism of biodegrada- tion in polymers such as polylactides is by hydrolysis of ester linkages.
SUMMARY OF THE INVENTION
This invention comprises a process for microencap- sulating a core material such that the resulting microcapsule has reduced residual solvent and reduced water content. In one embodiment of this invention, the microsphere has reduced residual solvent with no residual water present. The process of this invention involves the steps of:
(a) dissolving a polymeric coating material in an organic solvent in which the core material is not soluble;
(b) adding a core material;
(c) adding a first non-solvent of the polymer selected from synthetic oil or vegetable oil compounds in a ratio of first non-solvent to the organic solvent of from about 1:5 wt/wt to about 3:1 wt/wt to form embryonic microcap¬ sules; and
(d) adding a second non-solvent of the polymer to harden the embryonic microspheres and to extract the first non-solvent from the microspheres.
The invention also comprises microspheres compris¬ ing a core material encapsulated by a polymer coating, the microspheres having a residual solvent content of, about one percent.
The inventors have discovered that the use of synthetic oils or vegetable oil compounds as the first non-solvent in combination with the high ratio of the first non-solvent to the organic solvent for the polymeric coating material reduces the residual solvent in the final microsphere product. By use of this
invention it is possible to reduce the level of residual solvent in the microspheres.
In one embodiment of this invention, when solid particles to be encapsulated are used, the final microspheres will have a reduced residual solvent with no residual water content. Thus, the invention also comprises microspheres comprising a core material encapsulated by a polymer coating, the microspheres having a reduced residual solvent content of about one percent and with no residual water present.
pT-TATf-Tϋr. nT-RCRIPTION OF THE PREFERRED EMBODIMENTS The process of this invention is based on a phase separation technique to microencapsulate a core materi¬ al. The general process of this invention involves the following steps:
(a) dissolving a polymeric coating material in an organic solvent;
(b) adding the core material as solid particles to form a suspension or as an aqueous solution to form a water-in-oil emulsion;
(c) adding a first non-solvent of the polymer, either synthetic oils or vegetable oils, in a ratio of first non-solvent to organic solvent of from about 1:5 wt/wt to about 3:1 wt/wt, to cause the polymer to precipitate onto the solid particles or around the water droplets to form embryonic microcapsules; and
(d) quenching with a second non-solvent of the polymer, to harden the microcapsules.
After the quenching step, the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere
product. By the process of this invention, a final microsphere product is produced that has a residual solvent level of less than one percent. By residual solvent is meant the level of residual second non- solvent that remains in the final microsphere product. There will also be a remaining amount of organic solvent that remains in the final microcapsule product, typi¬ cally ethylene chloride. The methylene chloride level is vacuum extractable to 0.1 % or less. As used herein, the ratios are based on a weight/weight ratio.
In the preferred embodiment of this invention, the general process of the invention involves the following steps:
(a) dissolving a polymeric coating material in an organic solvent;
(b) adding the core material as solid particles to form a suspension;
(c) adding a first non-solvent of the polymer, either synthetic oils or vegetable oils, in a ratio of first non-solvent to organic solvent of from about 1:5 wt/wt to about 3:1 wt/wt, to cause the polymer to precipitate onto the solid particles or around the water droplets to form embryonic microcapsules; and
(d) quenching with a second non-solvent of the polymer, to harden the microcapsules.
After the quenching step, the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product. By the process of this invention wherein the core material is added as solid particles, a final microsphere product is produced that has a residual solvent level of less than one percent and a reduced water content.
The core material that may be used in this inven¬ tion can include any material that is not soluble or miscible with the polymeric coating material or the organic solvent for the polymer or the first or second non-solvent for the polymer.
The polymeric coating material that may be used in this invention may be either natural or synthetic polymers, or combinations thereof. The polymers may include cellulosic polymers, polyvinyl acetate, poly¬ vinyl alcohol, polyvinyl chloride, natural and synthetic rubbers, polyacrylates, polyorthoesters, and the like.
Specific examples include polystyrene, ethyl- cellulose, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylaminohydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly- (meth)acrylic acid ester, polyvinylacetal-diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate- ethaσrylic acid copolymer, polycarbonate, polyesters, polypropylene, vinylchloride-vinylacetate copolymer, polysaccharides, and glycerol distearate.
Suitable polymers for use with a pharmaceutical core material include biodegradable polymers such as polyanhydrides and aliphatic polyesters including polylactide, polylactide-co-glycolide polyglycolide, polycaprolactone, polylactide-co-caprolactone, poly- hydroxybutyride, polyanhydride, polydioxanone, and copolymers thereof such as poly(lactide-co-glycolide) copolymer and polylactide homopolymer.
The organic solvent that may be used according to this invention to dissolve the polymeric coating material must be a material which will dissolve the polymeric coating material and which will not dissolve the core material to be encapsulated. If the core
material is a pharmaceutical compound, then the organic solvent must also be chemically inert with respect to any pharmaceutical compounds to be encapsulated.
The organic solvent can be selected from a variety of common organic solvents including halogenated aliphatic hydrocarbons, typically the C^ to c4 halo¬ genated alkanes, such as, for example, chloroform, methylene chloride, ethylene dichloride, ethylene chloride, ethyl acetate, methylchloroform and the like; aromatic hydrocarbon compounds, halogenated aromatic hydrocarbon compounds; cyclic ethers such as tetrahydro- furan and the like.
The first non-solvent for the polymer according to this invention may be selected from synthetic oils or vegetable oil compounds. Synthetic oils may include silicone oil, mineral oil, and petroleum oils. Vege¬ table oils may include sesame oil, peanut oil, soybean oil, corn oil, cotton seed oil, coconut oil, linseed oil, and other related oils. By non-solvent is meant a solvent that is miscible with the organic solvent but is not a solvent for the polymeric coating or core materi¬ al. The inventors have discovered that the amount and type of the first non-solvent for the polymer controls the level of residual solvent (second non-solvent) in the final microsphere product. According to this invention, the ratio of first non-solvent to organic solvent is from about 1:5 to about 3:1. Further, in one embodiment of this invention, by employing solid drug particles rather than aqueous solutions or suspensions of drug, no residual water is present in the final product.
The polymeric coating material is dissolved in the selected organic solvent prior to adding the core
material. The amount of polymeric coating material dissolved in the solvent is typically from about 5 to 50 percent.
The core material is then added to the polymer- solvent solution, preferably, as solid particles to form a suspension or as an aqueous solution to form a water- in-oil emulsion. The amount of core material added to the polymer-solvent solution is not critical, although the ratio of core material to polymer is important insofar as that at too high an amount of core material to polymer, microspheres will not form. Typically, the upper limit of the ratio of core material to polymer may be about 80 parts by weight core material to about 20 parts by weight polymer. There is no lower limit to the ratio at which the core material can be combined with the polymeric coating material, except that at very low loadings of core material in the microcapsules, the microcapsules would not be practically useful.
Typically in the process of this invention, core material is added to the polymer-solvent solution such that the core material comprises about 5 to 50 weight percent.
The first non-solvent, synthetic oil or vegetable oil, in an amount of the ratio of about 1:5 to about 3:0, first non-solvent to organic solvent, is then added slowly to the mixture of polymeric solvent solution with the added core material. The first non-solvent causes the polymeric material to precipitate out of the organic solvent onto the core material, thereby encapsulating the core material. The first non-solvent is added under carefully controlled conditions of temperature, rate, and stir speed. For example, temperature conditions may range from -20 degrees C to +30 degrees C; rate 5
g/minutes per g of batch; stir speed from 400 to 2500 rpm.
Following the isolation of the microspheres, the microspheres are treated in a quenching step to harden them. In this step, the microspheres are quenched with a second non-solvent. This second non-solvent hardens the microspheres and extracts the solvent from the microspheres and yet does not dissolve the microspheres (wall material or core material) .
The amount of second non-solvent added in this quenching step is typically from about 0.251/g of batch to about 1 1/g of batch. Suitable second non-solvents include heptane and aliphatic hydrocarbons such as hexanes.
After the solvent has been removed from the microspheres, the microspheres are isolated, such as by filtration or sieving, and are dried by exposure to air or by other conventional drying techniques, such as vacuum drying, drying over a dessicant, or the like. Preferably, the microspheres are dried under a vacuum at room temperature to further reduce the level of organic solvent in the final microsphere product.
As has been found from experimentation, in conven¬ tional phase-separation techniques, 5 to 10% residual solvent (heptane) is usually present in the finished product. By the process according to this invention, the residual solvent content is about one percent.
Thus, by the process of this invention a final microsphere product is produced that contains about one percent residual solvent. In the preferred embodiment, the inal microsphere product contains about one percent residual solvent with no residual water present. The microsphere product of the present invention is usually
made up of particles of a spherical shape although sometimes the microspheres may be irregularly shaped. The microspheres can vary in size, ranging from sub- micron to millimeter diameters. Preferably, εubmicron to 250 urn diameters are desirable for pharmaceutical formulations allowing administration of the microspheres with a standard syringe and needle. The microspheres find utility in a wide variety of applications depending upon the encapsulated core compound. Advantageously, the microsphere product, according to this invention, is an encapsulated pharmaceutical compound which can be administered to both humans and animals.
The core material that may be used in the process of this invention may include agricultural agents, such as insecticides, fungicides, herbicides, rodenticides, pesticides, fertilizers, and viruses for crop protection and the like; cosmetic agents, such as deodorants, fragrances, and the like; food additives such as flavors; and pharmaceutical agents.
Pharmaceutical compounds are the preferred core materials of the process according to this invention. These compounds may also include the non-toxic pharma¬ ceutically acceptable acid addition salts, such as hydrochloride, εulfate, phosphate, succinate, benzoate, acetate, pamoate, fu erate, mesylate, and the like. Among the pharmaceutical drugs which may be utilized are the following: contraceptive agents including estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol, and the like; progestins such as norethindrone, norgestryl, ethynodiol diacetate, lynestrenol, medroxyprogesterone acetate, dimethi- sterone, megestrol acetate, chlormadinone acetate, norgestimate, norethisterone, ethisterone, melengestrol,
norethynodrel and the like; and spermicidal compounds such as nonylphenoxypolyoxyethylene glycol, benzethoniu chloride, chlorindanol and the like. Other biologically active agents which can be incorporated in the present microcapsules include gastrointestinal therapeutic agents such as aluminum hydroxide, calcium carbonate, magnesium carbonate, sodium carbonate and the like; non- steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; major tranquilizers such as chloropromazine HC1, clozapine, mesoridazine, metiapine, reserpine, thioridazine and the like; micro tranquilizers such as chlordiazepoxide, diazepam, meprobamate, temezepam and the like; rhinological decongestants, sedative-hypnotics such as codeine, phenobarbital, sodium pentobarbital, sodium secobarbital and the like; other steroids such as testosterone and testosterone propionate; sulfonamides; sympathomimetic agents; vaccines; vitamins and nutrients such as the essential amino acids, essential fats and the like; antimalarials such as 4-aminoquinolines, 8-amino- quinolines, pyrimethamine and the like; anti-migraine agents such as mazindol, phentermine and the like; anti- Parkinson agents such as L-dopa; anti-spasmodics such as atropine, methscopola ine bromide and the like; anti- spasmodics and anticholinergic agents such as bile therapy, digestants, enzymes and the like; anti-tussives such as dextromethorphan, noscapine and the like; bronchodilators, cardiovascular agents such as anti- hypertensive compounds, Rauwolfia alkaloids, coronary vasodilators, nitroglycerin, organic nitrates, penta- erythritotetranitrate and the like; electrolyte replace¬ ments such as potassium chloride, ergotalkaloids such as ergota ine with and without caffeine, hydrogenated ergot
alkaloids, dihydroergocristine methanesulfate, dihydro- ergocornine ethanesulfonate, dihydroergokroyptine methanesulfate and combinations thereof, alkaloids such as atropine sulfate. Belladonna, hyoscine hydrobromide and the like; analgetics; narcotics such as codeine, dihydrocodienone, meperidine, morphine and the like; non-narcotics such as εaliσylates, aspirin, acetamino¬ phen, d-propoxyphene and the like; antibiotics such as the cephalosporins, chloranphenical, gentamicin, Kanamycin A, Kanamycin B, the penicillins, ampicillin, streptomycin A, antimycin A, chloropamtheniol, metromi- dazole, oxytetracycline penicillin G, the tetracyclines, and the like; anti-cancer agent; anti-convulsants such as mephenytoin, phenobarbital, trimethadione; anti- emetics such as thietylperazine; antihistamines such as chlorophinazine, dimenhydrinate, diphenhydramine, perphenazine, tripelennamine and the like; anti-inflam¬ matory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopuri- nol, aspirin, indomethacin, phenylbutazone and the like; prostaglandins; cytotoxic drugs such as thiotepa, chlorambucil, cyclophospha ide, melphalan, nitrogen mustard, methotrexate and the like; antigens of such microorganisms as Neisseria gonorrhea. Mvcobacterium tuberculosis. Herpes virus (hu onis, types 1 and 2), Candida albicans. Candida tropicalis. Trichomonas vaqinalis. Haemophilus vaginalis. Group B streptococcus E. coli. gtrep. mutans. Microplasma hominis. Heπophilus ducreyi. Granuloma inguinale, Lv phopathia venereum, Treponema pallidum. Brucella abortus,. Brucella πieliten- sis. Brucella suis. Brucella canis. Ca pylobacter fetus. Campylobacter fetus intestinalis. Leptospira pomona, Listeria moncvtoqenes. Brucella ovis. Equine herpes
virus 1, Equine arteritis virus, IBR-IBP virus, BVD-MB virus, Chlamvdia psittaci. Trichomonas foetus. Toxo- plasma σondii. Escherichia coli. Actinobaccillus e uuli. Salmonella abortus ovis. Salmonella abortus eσui. Pseudomonas aeruginosa. Corynebacterium equi. Corvnebac- terium pyogenes. Actinobaccilus seminis. Mvσoplasma bovigenitaliu f Asperσillus fumjqatus, Absidia ramosa. Trypanosoma equiperdum. Babesia caballi. Clostridium tetani. and the like; antibodies which counteract the above microorganisms; and enzymes such as ribonuclease, neuramidinase, trypsin, glycogen phosphorylase, sperm lactic dehydrogenase, sperm hyaluronidase, adenoεsine- triphosphataεe, alkaline phoεphataεe, alkaline phospha- taεe esterase, a ino peptidase, trypsin chymotrypsin, amylase, muramidaεe, acrosomal proteinase, diesterase, glutamic acid dehydrogenase, succinic acid dehydroge¬ nase, betaglycophosphatase, lipase, ATP-ase alpha- peptate gama-glutamylotranspeptidase, εterol-3-beta-ol- dehydrogenase, DPN-di-aprorase.
Other compounds of particular interest are hormon- ally active polypeptides, especially luteininzing hormone-releasing hormone (LR-RH) polypeptides, ana¬ logues, and antagonists thereof; mammalian growth hormones, including human, bovine, equine, and sheep growth hormones; alpha, beta, gamma, and omega interferon; interleukin I and interleukin II; and erythropoietin.
Having generally described the invention, further understanding can be obtained by reference to certain specific examples which are provided herein for purpose of illustration only and are not intended to be limiting unless otherwise specified.
EXΑMPIJ5 I
This example describes the procedure for preparing microspheres, varying the ratio of the first non- solvent, silicone oil, to the organic εolvent, methylene chloride.
The polymeric coating material, a copolymer with a 50:50 molar ratio of lactide:glycolide units with inherent viscosity of 0.69 dl/g, was weighed and dissolved in methylene chloride (CH2Cl2) . The encapsu¬ late, histrelin, was dispersed in the solvent/polymer mixture using a stirrer. With continued stirring, silicone oil waε added to the mixture. The ratio of the silicone oil to the methylene chloride εolvent was varied in these experiments and the resultε are shown in the following Table 1. The εilicone oil cauεed the polymer to phaεe separate, and depoεit as droplets of solvent-fluid polymer onto the surface of the water- εoluble microdropletε. These solvent-fluid polymer droplets then coalesced to form a continuous film around the water-soluble microdroplets.
The microspheres were then hardened by quenching by pouring the contents of this first mixture into a beaker containing heptane. The heptane/methylene chloride/- εilicone oil εolution waε removed by filtration. The microspheres were further washed with aliquots of heptane. The microspheres were dried at room tempera¬ ture under vacuum. The microsphereε obtained from this preparation were determined to have diameters ranging in size from 25 to 150 microns.
The following Table 1 gives the resultε of the teεtingε to εhow the effect of the ratio of eilicone oil to methylene chloride and the effect of the viεcosity of
the εilicone oil. The viεcoεity of the εilicone oil was studied at 200cε, 350cs, and 500cs. In three of the tests, histrelin was used as the encapsulate; with the other testε a placebo was used.
* Vacuum extractable to 0.8%
** Loaded encapsulate = histrelin
EXAMPLE II
■Silicone Oil 1:2.6 Ratio rwt/wt. of First Non-Solvent to Solvent
A 50:50 lactide:glycolide copolymer, 1.80 g, was disεolved in 15.7 g of methylene chloride and charged to a 100 ml flask. Histrelin, 200.4 mg, was suspended in 12.2 g of methylene chloride and added with εtirring to the polymer εolution. An additional 6.0 g of methylene chloride waε then added (total = 33.9 g) . Silicone oil
(350 cs), 13.13 g was added over 8.5 minutes. Then, the contents of the reaction flask were tranεferred to 2800 ml of n-heptane with εtirring at 21*C. Stirring was continued for 3 hours. The microεpheres were collected on stain ess-εteel sieves and allowed to air dry. The reεidual heptane content waε found to be 8.7% by weight. The hiεtrelin content was 7.76% by weight.
E AMP ; HT
Silicone Oil 1.9:1 Ratio of First Non-Solvent to Solvent
1.8 g of a 50:50 lactiderglycolide copolymer was dissolved in 15.0 g of methylene chloride. Histrelin, 201.5 mg, was suspended in 15.0 g of methylene chloride and sonicated briefly to disperse the drug. The disperεion waε then added with εtirring to the polymer εolution. An additional 12.67 g of methylene chloride waε added to the reaction flaεk. Silicone oil (350 cs) , 82.17 g, was added over 13 minutes. The contents of the reaction flaεk were tranεferred to 3250 ml of n-heptane with εtirring at 18.2*C. Stirring waε continued for 3 hourε. The microcapεuleε were collected on εtainless- εteel sieves and allowed to air dry. Reεidual heptane waε found to be 0.9% by weight. Hiεtrelin content was 8.35% by weight.
The foregoing invention has been deεcribed in some detail by way of illustration and example for purposes of clarity and understanding. It will be obvious that certain changes and modifications may be practiced within the scope of the invention, aε limited only by εcope of the appended claims.
Claims
1. A process for the preparation of microspheres comprising a core material encapsulated by a polymer coating comprising:
(a) dissolving a polymer coating material in an organic solvent in which the core material iε not soluble to form a polymer-organic εolvent mixture;
(b) adding the core material to said mixture;
(c) adding a first non-solvent of the polymer selected from εynthetic oil or vegetable oil in a ratio of first non-solvent to organic solvent of from about 1.5:1 wt/wt to about 3:1 wt/wt to the core material- containing mixture to form embryonic microspheres; and
(d) quenching said embryonic microspheres with a second non-solvent of the polymer to produce microspheres.
2. The process of claim 1 wherein said polymer coating material is selected from the group consiεting of celluloεic polymerε, polyvinyl acetate, polyvinyl alcohol, polyvinyl chloride, natural and εynthetic rubberε, polyacrylateε and polyorthoesters.
3. The process of claim 1 wherein said polymer coating material iε εelected from the group consisting of polystyrene, ethyicellulose, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylaminohydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly(meth)acrylic acid ester, poly- vinylacetal-diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate-methacrylic acid copolymer, polycarbonate, polyeεterε, polypropylene, vinylchloride- vinylacetate copolymer, polysaccharides, and glycerol diεtearate.
4. The process of claim 1 wherein εaid polymer coating material iε a biodegradable polymer selected from the group consiεting of polylactide, polylactide- co-glycolide polyglycolide, polycaprolactone, poly- lactide-co-caprolactone, polyhydroxybutyride, poly- anhydride, polydioxanone, and copolymerε thereof.
5. The proceεε of claim 1 wherein the polymer coating material iε a selected from the group consiεting of poly(lactide-co-glycolide) and polylactide.
6. The proceεs of claim 1 wherein said organic solvent is selected from chloroform, methylene chloride, tetrahydrofuran, and ethyl acetate.
7. The process of claim 1 wherein εaid firεt non- εolvent iε selected from silicone oil, mineral oil, petroleum oil, εeεame oil, peanut oil, εoybean oil, corn oil, cotton seed oil, coconut oil, and linseed oil.
8. The process of claim 6 wherein εaid first non- solvent is εeεame oil or εilicone oil.
9. The proceεs of claim 1 wherein εaid εecond non-εolvent iε εelected from heptane, hexaneε or pentane.
10. The proceεε of claim 1 wherein said core material compriseε solid particles and is added to εaid mixture in εtep (b) to form a εuspension.
11. The procesε of claim 1 wherein εaid core material comprises an aqueous solution and iε added to εaid mixture in εtep (b) to form a water-in-oil emul¬ sion..
12. The proceεε of claim 1 further compriεing treating εaid microεphere product by drying εaid microsphere product under a vacuum.
13. A procesε for producing microεphereε compriε¬ ing a core material encapsulated by a polymer coating wherein said microsphereε contain leεs than one percent residual εolvent and with no residual water content, comprising:
(a) disεolving a polymer coating material in an organic εolvent in which the core material iε not soluble to form a polymer-organic εolvent mixture;
(b) adding the core compound aε εolid particles to said mixture to form a suspension;
(c) adding a first non-εolvent of the polymer selected from εynthetic oil or vegetable oil in a ratio of first non-solvent to organic solvent of from about 1.5:1 wt/wt to about 3:1 wt/wt to the core material- containing mixture to form embryonic microcapsuleε; and
(d) quenching said embryonic microcapsules with a second non-solvent of the polymer to produce a final product containing about one percent residual εolvent.
14. Microcapεuleε produced by the proceεε of any of claims 1-13.
15. A microsphere comprising a core material encapsulated by a polymer coating, said microsphere having a residual εolvent content of one percent or leεε.
16. The microsphere of claim 15 wherein εaid polymer iε selected from the group consiεting of celluloεic polymerε, polyvinyl acetate, polyvinyl alcohol, polyvinyl chloride, natural and εynthetic rubbers, polyacrylates and polyorthoesters.
17. The microsphere of claim 15 wherein said polymer is selected from the group consiεting of polyεtyrene, ethylcelluloεe, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylamino- hydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly(meth)acrylic acid ester, polyvinylacetal- diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate-methacrylic acid copolymer, polycarbonate, polyesterε, polypropylene, vinylchloride-vinylacetate copolymer, polysaccharideε, and glycerol diεtearate.
18. The microεphere of claim 15 wherein εaid polymer iε a biodegradable polymer εelected from the group conεiεting of polylactide, polylactide-co-glyco- lide polyglycolide, polycaprolactone, polylactide-co- caprolactone, polyhydroxybutyride, polyanhydride, polydioxanone, and copolymerε thereof.
19. The microεphere of claim 15 wherein εaid core material iε a luteinizing hormone-releasing hormone (LH- RH) peptide, analog, or antagoniεt.
20. The microεphere of claim 15 wherein said core material is growth hormone.
21. The microsphere of claim 15 wherein εaid core material is alpha, beta, gamma, or omega interferon.
22. The microεphere of claim 15 wherein said core material iε erythropoietin.
22. The microεphere of claim 15 wherein said core material iε interleukin I or interleukin II.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11492187A | 1987-10-30 | 1987-10-30 | |
US114,921 | 1987-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989003678A1 true WO1989003678A1 (en) | 1989-05-05 |
Family
ID=22358249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/003859 WO1989003678A1 (en) | 1987-10-30 | 1988-10-31 | Low residual solvent microspheres and microencapsulation process |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2810189A (en) |
WO (1) | WO1989003678A1 (en) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000070A1 (en) * | 1991-06-28 | 1993-01-07 | Endorecherche Inc. | Controlled release systems and low dose androgens |
EP0543841A4 (en) * | 1990-07-13 | 1993-03-01 | Du Pont | Degradable resins for electrostatic liquid developers. |
WO1993025221A1 (en) * | 1992-06-11 | 1993-12-23 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
EP0576377A1 (en) * | 1992-06-24 | 1993-12-29 | FLAMEL TECHNOLOGIES, Société Anonyme | Microcapsules containing at least an active principle, their applications and one of their processes of preparation |
US5362720A (en) * | 1991-06-28 | 1994-11-08 | Endorecherche, Inc. | Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
US5654008A (en) * | 1993-11-19 | 1997-08-05 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
WO1998007442A1 (en) * | 1996-08-23 | 1998-02-26 | International Centre For Genetic Engineering And Biotechnology | Sustained-release preparation comprising erythropoietin and polylactide coglycolide |
US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5916597A (en) * | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
WO1999036071A1 (en) * | 1998-01-19 | 1999-07-22 | Korea Research Institute Of Chemical Technology | Biodegradable polymer matrices for sustained delivery of anesthetics |
WO1999036057A1 (en) * | 1998-01-19 | 1999-07-22 | Korea Research Institute Of Chemical Technology | Controlled releasing antibiotics preparation |
WO1999047588A1 (en) * | 1998-03-14 | 1999-09-23 | Cenes Drug Delivery Limited | Production of microparticles |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
AT406017B (en) * | 1993-05-15 | 2000-01-25 | Sod Conseils Rech Applic | METHOD FOR PRODUCING PARTICLES, PARTICULAR OBTAINED, AND PHARMACEUTICAL MEASURES CONTAINING SUCH PARTICLES |
US6331317B1 (en) | 1999-11-12 | 2001-12-18 | Alkermes Controlled Therapeutics Ii Inc. | Apparatus and method for preparing microparticles |
US6379704B2 (en) | 2000-05-19 | 2002-04-30 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US6379703B1 (en) | 1998-12-30 | 2002-04-30 | Alkermes Controlled Therapeutics Inc., Ii | Preparation of microparticles having a selected release profile |
EP1234670A2 (en) | 2001-02-27 | 2002-08-28 | Imaje S.A. | Printhead and printer with improved deflection electrodes |
US6495166B1 (en) | 1999-11-12 | 2002-12-17 | Alkermes Controlled Therapeutics Inc. | Apparatus and method for preparing microparticles using in-line solvent extraction |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US6705757B2 (en) | 1999-11-12 | 2004-03-16 | Alkermes Controlled Therapeutics, Inc. Ii | Method and apparatus for preparing microparticles using in-line solvent extraction |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US6830737B2 (en) | 2000-09-27 | 2004-12-14 | Alkermes Controlled Therapeutics Inc. Ii | Apparatus for preparing microparticles using liquid-liquid extraction |
EP1728550A1 (en) * | 2004-03-23 | 2006-12-06 | Kyowa Hakko Kogyo Co., Ltd. | Method for producing coated fine particles |
US7247319B2 (en) | 2000-12-27 | 2007-07-24 | Alkermes, Inc. | Preparation of microparticles having improved flowability |
US8877252B2 (en) | 2004-04-15 | 2014-11-04 | Alkermes Pharma Ireland Limited | Polymer-based sustained release device |
WO2016007468A1 (en) * | 2014-07-07 | 2016-01-14 | AntriaBio | Solvent extraction from biodegradable microparticles |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CN108969494A (en) * | 2018-09-25 | 2018-12-11 | 珠海赛隆药业股份有限公司 | A kind of Parecoxib Sodium durative action preparation and preparation method thereof |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
WO2021010814A3 (en) * | 2019-07-15 | 2021-04-15 | Dva Farma Mexicana S.A. De C.V. | Compositions of film coatings for tablets with increased gloss, method for production thereof and application of same |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3971852A (en) * | 1973-06-12 | 1976-07-27 | Polak's Frutal Works, Inc. | Process of encapsulating an oil and product produced thereby |
US4244836A (en) * | 1978-02-07 | 1981-01-13 | Hoechst Aktiengesellschaft | Process for manufacturing microcapsules of polyvinyl alcohol with liquid water-insoluble content |
US4389331A (en) * | 1979-10-31 | 1983-06-21 | Tanabe Seiyaku Co., Ltd. | Process for preparing pharmaceutically active compound-containing microcapsules |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4479911A (en) * | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
EP0052510B1 (en) * | 1980-11-18 | 1986-08-27 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble polypeptides |
US4637905A (en) * | 1982-03-04 | 1987-01-20 | Batelle Development Corporation | Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones |
US4673595A (en) * | 1984-10-17 | 1987-06-16 | Debiopharm, S.A. | Microencapsulation by phase separation of water-soluble medicaments |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4711782A (en) * | 1983-11-04 | 1987-12-08 | Takeda Chemical Industries, Ltd. | Prolonged release microcapsules and their production |
US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
US4766012A (en) * | 1985-08-29 | 1988-08-23 | Farmaceutici Formenti S.P.A. | Microencapsulation of a medicament |
-
1988
- 1988-10-31 AU AU28101/89A patent/AU2810189A/en not_active Abandoned
- 1988-10-31 WO PCT/US1988/003859 patent/WO1989003678A1/en unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3971852A (en) * | 1973-06-12 | 1976-07-27 | Polak's Frutal Works, Inc. | Process of encapsulating an oil and product produced thereby |
US4244836A (en) * | 1978-02-07 | 1981-01-13 | Hoechst Aktiengesellschaft | Process for manufacturing microcapsules of polyvinyl alcohol with liquid water-insoluble content |
US4389331A (en) * | 1979-10-31 | 1983-06-21 | Tanabe Seiyaku Co., Ltd. | Process for preparing pharmaceutically active compound-containing microcapsules |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
EP0052510B1 (en) * | 1980-11-18 | 1986-08-27 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble polypeptides |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US4479911A (en) * | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
US4637905A (en) * | 1982-03-04 | 1987-01-20 | Batelle Development Corporation | Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones |
US4711782A (en) * | 1983-11-04 | 1987-12-08 | Takeda Chemical Industries, Ltd. | Prolonged release microcapsules and their production |
US4673595A (en) * | 1984-10-17 | 1987-06-16 | Debiopharm, S.A. | Microencapsulation by phase separation of water-soluble medicaments |
US4766012A (en) * | 1985-08-29 | 1988-08-23 | Farmaceutici Formenti S.P.A. | Microencapsulation of a medicament |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0543841A1 (en) * | 1990-07-13 | 1993-06-02 | E.I. Du Pont De Nemours And Company | Degradable resins for electrostatic liquid developers |
EP0543841A4 (en) * | 1990-07-13 | 1993-03-01 | Du Pont | Degradable resins for electrostatic liquid developers. |
US5753639A (en) * | 1991-06-28 | 1998-05-19 | Endorecherche Inc. | Low dose androgenic compounds for prevention and treatment of endometriosis |
US5629303A (en) * | 1991-06-28 | 1997-05-13 | Endorecherche Inc. | Controlled release systems and low dose androgens |
WO1993000070A1 (en) * | 1991-06-28 | 1993-01-07 | Endorecherche Inc. | Controlled release systems and low dose androgens |
US5545634A (en) * | 1991-06-28 | 1996-08-13 | Endorecherche, Inc. | Activation of androgen receptors with low dose non-masculinizing androgenic compounds |
US5362720A (en) * | 1991-06-28 | 1994-11-08 | Endorecherche, Inc. | Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds |
US5434146A (en) * | 1991-06-28 | 1995-07-18 | Endorecherche, Inc. | Controlled release systems and low dose androgens |
US5541172A (en) * | 1991-06-28 | 1996-07-30 | Endorecherche, Inc. | Controlled release systems and low dose androgens |
US5846960A (en) * | 1991-06-28 | 1998-12-08 | Endorecherche, Inc. | Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds |
US5567695A (en) * | 1991-06-28 | 1996-10-22 | Endorecherche, Inc. | Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds |
US5861387A (en) * | 1991-06-28 | 1999-01-19 | Endorecherche Inc. | Controlled release systems and low dose androgens |
US6749866B2 (en) | 1992-03-12 | 2004-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6368630B1 (en) | 1992-03-12 | 2002-04-09 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
AU698016B2 (en) * | 1992-06-11 | 1998-10-22 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
WO1993025221A1 (en) * | 1992-06-11 | 1993-12-23 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
EP0576377A1 (en) * | 1992-06-24 | 1993-12-29 | FLAMEL TECHNOLOGIES, Société Anonyme | Microcapsules containing at least an active principle, their applications and one of their processes of preparation |
FR2692812A1 (en) * | 1992-06-24 | 1993-12-31 | Flamel Tech Sa | Microcapsules containing at least one active principle, their applications and process for preparing microcapsules containing at least one active principle. |
US5585050A (en) * | 1992-06-24 | 1996-12-17 | Flamel Technologies | Microcapsules containing at least one active ingredient, application of such capsules and one of their preparation methods |
AT406017B (en) * | 1993-05-15 | 2000-01-25 | Sod Conseils Rech Applic | METHOD FOR PRODUCING PARTICLES, PARTICULAR OBTAINED, AND PHARMACEUTICAL MEASURES CONTAINING SUCH PARTICLES |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
US5654008A (en) * | 1993-11-19 | 1997-08-05 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
US6358443B1 (en) | 1995-05-18 | 2002-03-19 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US6726860B2 (en) | 1995-05-18 | 2004-04-27 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US7037450B2 (en) | 1995-05-18 | 2006-05-02 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US6153129A (en) * | 1995-05-18 | 2000-11-28 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US5916597A (en) * | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US5916598A (en) * | 1996-05-07 | 1999-06-29 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
US6110503A (en) * | 1996-05-07 | 2000-08-29 | Alkermes Controlled Therapeutics Inc. | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US6403114B1 (en) | 1996-05-07 | 2002-06-11 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
WO1998007442A1 (en) * | 1996-08-23 | 1998-02-26 | International Centre For Genetic Engineering And Biotechnology | Sustained-release preparation comprising erythropoietin and polylactide coglycolide |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
WO1999036071A1 (en) * | 1998-01-19 | 1999-07-22 | Korea Research Institute Of Chemical Technology | Biodegradable polymer matrices for sustained delivery of anesthetics |
WO1999036057A1 (en) * | 1998-01-19 | 1999-07-22 | Korea Research Institute Of Chemical Technology | Controlled releasing antibiotics preparation |
WO1999047588A1 (en) * | 1998-03-14 | 1999-09-23 | Cenes Drug Delivery Limited | Production of microparticles |
US6596316B2 (en) | 1998-12-30 | 2003-07-22 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of microparticles having a selected release profile |
US6379703B1 (en) | 1998-12-30 | 2002-04-30 | Alkermes Controlled Therapeutics Inc., Ii | Preparation of microparticles having a selected release profile |
US6861016B2 (en) | 1999-11-12 | 2005-03-01 | Alkermes Controlled Therapeutics Inc. Ii | Apparatus and method for preparing microparticles |
US7300671B2 (en) | 1999-11-12 | 2007-11-27 | Alkermes, Inc. | Method and apparatus for preparing microparticles using in-line solvent extraction |
US7510730B2 (en) | 1999-11-12 | 2009-03-31 | Alkermes, Inc. | Apparatus and method for preparing microparticles using in-line solvent extraction |
US6537586B2 (en) | 1999-11-12 | 2003-03-25 | Alkermes Controlled Therapeutics Inc. Ii | Apparatus and method for preparing microparticles |
US6540393B1 (en) | 1999-11-12 | 2003-04-01 | Alkermes Controlled Therapeutics Inc. Ii | Apparatus for preparing microparticles using in-line solvent extraction |
US6495166B1 (en) | 1999-11-12 | 2002-12-17 | Alkermes Controlled Therapeutics Inc. | Apparatus and method for preparing microparticles using in-line solvent extraction |
US6395304B2 (en) | 1999-11-12 | 2002-05-28 | Alkermes Controlled Therapeutics Inc. Ii | Apparatus and method for preparing microparticles |
US6705757B2 (en) | 1999-11-12 | 2004-03-16 | Alkermes Controlled Therapeutics, Inc. Ii | Method and apparatus for preparing microparticles using in-line solvent extraction |
US6713090B2 (en) | 1999-11-12 | 2004-03-30 | Alkermas Controlled Therapeutics Inc. Ii | Apparatus and method for preparing microparticles |
US6331317B1 (en) | 1999-11-12 | 2001-12-18 | Alkermes Controlled Therapeutics Ii Inc. | Apparatus and method for preparing microparticles |
US6939033B2 (en) | 1999-11-12 | 2005-09-06 | Alkermes Controlled Therapeutics, Inc. Ii | Method and apparatus for preparing microparticles using in-line solvent extraction |
US6379704B2 (en) | 2000-05-19 | 2002-04-30 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US6534092B2 (en) | 2000-05-19 | 2003-03-18 | Alkermes Controlled Therapeutics, Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US7799345B2 (en) | 2000-05-25 | 2010-09-21 | Alkermes Controlled Therapeutics, Inc. | Preparation of injectable suspensions having improved injectability |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US6667061B2 (en) | 2000-05-25 | 2003-12-23 | Alkermes Controlled Therapeutics, Inc. | Preparation of injectable suspensions having improved injectability |
US7371406B2 (en) | 2000-05-25 | 2008-05-13 | Alkermes Controlled Therapeutics, Inc. | Preparation of injectable suspensions having improved injectability |
US6830737B2 (en) | 2000-09-27 | 2004-12-14 | Alkermes Controlled Therapeutics Inc. Ii | Apparatus for preparing microparticles using liquid-liquid extraction |
US6884372B2 (en) | 2000-09-27 | 2005-04-26 | Alkermes Controlled Therapeutics, Inc. Ii | Method for preparing microparticles using liquid-liquid extraction |
US7247319B2 (en) | 2000-12-27 | 2007-07-24 | Alkermes, Inc. | Preparation of microparticles having improved flowability |
EP1234670A2 (en) | 2001-02-27 | 2002-08-28 | Imaje S.A. | Printhead and printer with improved deflection electrodes |
JP2011037882A (en) * | 2001-08-31 | 2011-02-24 | Alkermes Inc | Method for extracting residual solvent and microparticle produced thereby |
JP2013216676A (en) * | 2001-08-31 | 2013-10-24 | Alkermes Pharma Ireland Ltd | Residual solvent extraction method, and microparticle prepared by the same |
US7223440B2 (en) | 2001-08-31 | 2007-05-29 | Alkermes, Inc. | Residual solvent extraction method and microparticles produced thereby |
JP2015227383A (en) * | 2001-08-31 | 2015-12-17 | アルカームズ ファーマ アイルランド リミテッド | Residual solvent extraction method and microparticles produced thereby |
US7524530B2 (en) | 2001-08-31 | 2009-04-28 | Alkermes, Inc. | Residual solvent extraction method and microparticles produced thereby |
JP2005502674A (en) * | 2001-08-31 | 2005-01-27 | アルカームズ コントロールド セラピューティクス,インコーポレイテッド ツー | Residual solvent extraction method and fine particles produced by the same |
US7875310B2 (en) | 2001-08-31 | 2011-01-25 | Alkermes, Inc. | Residual solvent extraction method and microparticles produced thereby |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US8187672B2 (en) | 2001-08-31 | 2012-05-29 | Alkermes Pharma Ireland Limited | Residual solvent extraction method and microparticles produced thereby |
EP1728550A1 (en) * | 2004-03-23 | 2006-12-06 | Kyowa Hakko Kogyo Co., Ltd. | Method for producing coated fine particles |
EP1728550A4 (en) * | 2004-03-23 | 2007-09-05 | Kyowa Hakko Kogyo Kk | Method for producing coated fine particles |
US8877252B2 (en) | 2004-04-15 | 2014-11-04 | Alkermes Pharma Ireland Limited | Polymer-based sustained release device |
US9238076B2 (en) | 2004-04-15 | 2016-01-19 | Alkermes Pharma Ireland Limited | Polymer-based sustained release device |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10869830B2 (en) | 2009-09-28 | 2020-12-22 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
WO2016007468A1 (en) * | 2014-07-07 | 2016-01-14 | AntriaBio | Solvent extraction from biodegradable microparticles |
US10137089B2 (en) | 2014-07-07 | 2018-11-27 | Rezolute, Inc | Solvent extraction from biodegradable microparticles |
AU2015288014C1 (en) * | 2014-07-07 | 2020-07-16 | Rezolute, Inc. | Solvent extraction from biodegradable microparticles |
US9532953B2 (en) | 2014-07-07 | 2017-01-03 | Antriabio, Inc. | Solvent extraction from biodegradable microparticles |
AU2015288014B2 (en) * | 2014-07-07 | 2020-04-16 | Rezolute, Inc. | Solvent extraction from biodegradable microparticles |
US9439864B2 (en) | 2014-07-07 | 2016-09-13 | Antriabio, Inc. | Solvent extraction from biodegradable microparticles |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10583080B2 (en) | 2014-09-30 | 2020-03-10 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11214607B2 (en) | 2016-05-16 | 2022-01-04 | Intarcia Therapeutics Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11840559B2 (en) | 2016-05-16 | 2023-12-12 | I2O Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD912249S1 (en) | 2016-06-02 | 2021-03-02 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD962433S1 (en) | 2016-06-02 | 2022-08-30 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US11654183B2 (en) | 2017-01-03 | 2023-05-23 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of exenatide and co-administration of a drug |
CN108969494A (en) * | 2018-09-25 | 2018-12-11 | 珠海赛隆药业股份有限公司 | A kind of Parecoxib Sodium durative action preparation and preparation method thereof |
WO2021010814A3 (en) * | 2019-07-15 | 2021-04-15 | Dva Farma Mexicana S.A. De C.V. | Compositions of film coatings for tablets with increased gloss, method for production thereof and application of same |
Also Published As
Publication number | Publication date |
---|---|
AU2810189A (en) | 1989-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1989003678A1 (en) | Low residual solvent microspheres and microencapsulation process | |
US4389330A (en) | Microencapsulation process | |
US5916598A (en) | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | |
EP0729353B1 (en) | Preparation of biodegradable microparticles containing a biologically active agent | |
Tice et al. | Preparation of injectable controlled-release microcapsules by a solvent-evaporation process | |
DE69928283T2 (en) | PREPARATION OF MICROPARTICLES WITH A SELECTED RELEASE PROFILE | |
US5650173A (en) | Preparation of biodegradable microparticles containing a biologically active agent | |
EP1210942A2 (en) | Microparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |